Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BetterLife Pharma Inc C.BETR

Alternate Symbol(s):  BETRF

Healthcare
BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as... see more

Recent & Breaking News (CSE:BETR)

BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Newsfile 4 days ago

BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire 8 days ago

BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001

GlobeNewswire April 3, 2024

BetterLife's 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University

GlobeNewswire March 4, 2024

BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001

GlobeNewswire January 2, 2024

BetterLife Announces Closing of a Private Placement

GlobeNewswire December 18, 2023

BetterLife Announces Extension of Warrants

GlobeNewswire November 30, 2023

US Patent and Trademark Office Publishes BetterLife's Comprehensive Patent for BETR-001 and Other LSD Derivatives

GlobeNewswire November 15, 2023

BetterLife Pharma to Host Investors Update Call on September 18, 2023

GlobeNewswire September 14, 2023

BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001

GlobeNewswire September 12, 2023

BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement

GlobeNewswire September 5, 2023

BetterLife Highlights American College of Physicians' Updated Guidelines for Treating Depression and Announces Closing of Private Placement

GlobeNewswire July 13, 2023

BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives

GlobeNewswire June 27, 2023

BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada

GlobeNewswire June 22, 2023

BetterLife Continues Progress on BETR-001 IND-Enabling Studies

GlobeNewswire June 8, 2023

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

GlobeNewswire April 25, 2023

BetterLife Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Newsfile April 24, 2023

BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 20, 2023

BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article

GlobeNewswire March 29, 2023

Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article

GlobeNewswire March 22, 2023